 |
Quick Links |
| Information by Disease |
|
|
|
| Cancer News |
|
|
|
| Conference Coverage |
|
|
|
| AZN | $44.82 | -0.37 (-0.82%)
| | NVS | $53.13 | -0.16 (-0.3%)
| | SNY | $37.67 | -0.01 (-0.03%)
| | GSK | $41.53 | 0.06 (0.14%)
|
|
|
Cervical Cancer
| Efaproxyn (efaproxiral |
Radiosensitizer |
Allo |
II |
| Gemzar (gemcitabine) |
Antimetabolite |
Eli Lilly |
III |
| HPV16 E6 and E7 peptide vaccine |
Vaccine |
NCI |
I |
| LutrinÒ(motexafin lutetium) |
Photodynamic therapy |
Pharmacyclics |
I |
| MEDI-517 HPV Vaccine |
Vaccine |
MedImmune |
II completed |
| Multikine |
Leukocyte interleukin injection |
CEL-SCI |
I |
| Oxaliplatin (eloxitan) |
Organoplatinum complex |
Sanofi-Aventis |
II |
| RSR-13 (efaproxiral) |
Radiation sensitizer |
Allos Therapeutics |
I |
| Taxotere (docetaxel) |
Taxoid |
Aventis |
II |
| VelcadeÔ(boretezomib) |
Proteosome inhibitor |
Millennium |
I |
|
For more information contact us at clinicaltrials@cancerconsultants.com
 |
 View Drugs in Pipeline By Disease |
 |
|
|
|
 |
|
 |
|
|
Patient Home
Meeting Calendar
